Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.

Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT.

PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.

2.

Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.

Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD.

BMC Cancer. 2017 Apr 4;17(1):241. doi: 10.1186/s12885-017-3237-1.

3.

Response to the Article "Multi-Ethnic Attitudes Toward Physician-Assisted Death in California and Hawai'i:" Selection of Respondents Creates Fatally Flawed Study.

Seitz RS, Koijane J, Hokama N.

J Palliat Med. 2016 Nov;19(11):1135. Epub 2016 Aug 8. No abstract available.

PMID:
27501353
4.

Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Apr 18;16:275. doi: 10.1186/s12885-016-2307-0. No abstract available.

5.

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Feb 23;16:143. doi: 10.1186/s12885-016-2198-0. Erratum in: BMC Cancer. 2016;16(1):275.

6.

Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients.

Wang X, Ring BZ, Seitz RS, Ross DT, Woolf K, Beck RA, Hicks DG, Yeh S.

BMC Clin Pathol. 2015 Dec 9;15:21. doi: 10.1186/s12907-015-0021-5. eCollection 2015.

7.

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

Bartlett JM, Bloom KJ, Piper T, Lawton TJ, van de Velde CJ, Ross DT, Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D.

J Clin Oncol. 2012 Dec 20;30(36):4477-84. doi: 10.1200/JCO.2012.42.8896. Epub 2012 Oct 8.

PMID:
23045591
8.

TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.

9.

Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness.

Shon W, Jenkins SM, Ross DT, Seitz RS, Beck RA, Ring BZ, Okuno SH, Gibson LE, Folpe AL.

J Cutan Pathol. 2011 Dec;38(12):961-6. doi: 10.1111/j.1600-0560.2011.01790.x.

PMID:
22050093
10.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604. Epub 2010 Jul 8.

11.

The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.

Hicks DG, Janarthanan BR, Vardarajan R, Kulkarni SA, Khoury T, Dim D, Budd GT, Yoder BJ, Tubbs R, Schreeder MT, Estopinal NC, Beck RA, Wang Y, Ring BZ, Seitz RS, Ross DT.

BMC Cancer. 2010 Mar 22;10:108. doi: 10.1186/1471-2407-10-108.

12.

A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.

Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, Arbogast S, Robert F, Schreeder MT, Ross DT.

Mod Pathol. 2009 Aug;22(8):1032-43. doi: 10.1038/modpathol.2009.60. Epub 2009 May 8.

13.

TLE3 as a candidate biomarker of response to taxane therapy.

Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT.

Breast Cancer Res. 2009;11(2):R17. doi: 10.1186/bcr2241. Epub 2009 Mar 23.

14.

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N.

Clin Cancer Res. 2008 Oct 15;14(20):6602-9. doi: 10.1158/1078-0432.CCR-08-0647.

15.

Lipoxygenase pathway receptor expression in ovarian cancer.

Rocconi RP, Kirby TO, Seitz RS, Beck R, Straughn JM Jr, Alvarez RD, Huh WK.

Reprod Sci. 2008 Apr;15(3):321-6. doi: 10.1177/1933719108316390.

PMID:
18421027
16.

Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancer.

Hanker AB, Morita S, Repasky GA, Ross DT, Seitz RS, Der CJ.

Methods Enzymol. 2008;439:53-72. doi: 10.1016/S0076-6879(07)00405-3.

PMID:
18374156
17.

Gene expression patterns within cell lines are predictive of chemosensitivity.

Ring BZ, Chang S, Ring LW, Seitz RS, Ross DT.

BMC Genomics. 2008 Feb 8;9:74. doi: 10.1186/1471-2164-9-74.

18.

A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.

Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, Varma S, Corless CL, Heinrich MC, Smith KS, Wang Z, Rubin B, Nielsen TO, Seitz RS, Ross DT, West RB, Cleary ML, van de Rijn M.

Am J Surg Pathol. 2008 Feb;32(2):210-8. doi: 10.1097/PAS.0b013e3181238cec.

PMID:
18223323
19.

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT.

J Clin Oncol. 2006 Jul 1;24(19):3039-47.

PMID:
16809728
20.

RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer.

Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM.

J Biol Chem. 2001 Nov 9;276(45):42259-67. Epub 2001 Aug 31.

21.

Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption.

Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM.

Cancer Res. 2000 Mar 1;60(5):1353-60.

22.

A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic.

Bronstein JM, Lallone RL, Seitz RS, Ellison GW, Myers LW.

Neurology. 1999 Jul 13;53(1):154-61.

PMID:
10408552
23.

Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice.

Stevens DB, Chen K, Seitz RS, Sercarz EE, Bronstein JM.

J Immunol. 1999 Jun 15;162(12):7501-9.

24.

Hospitalization in an urban homeless population: the Honolulu Urban Homeless Project.

Martell JV, Seitz RS, Harada JK, Kobayashi J, Sasaki VK, Wong C.

Ann Intern Med. 1992 Feb 15;116(4):299-303.

PMID:
1733384

Supplemental Content

Loading ...
Support Center